In addition, several emerging immunomodulatory antibodies, initially thought to mediate their activities primarily by antagonizing co-inhibitory checkpoints (CTLA-4) or agonizing co-stimulatory pathways (OX40 and GITR), may in fact be simply mediating depletion of regulatory T cells (Tregs) at the tumor site by inducing ADCC and ADCP [41–44]. This evidence concerns the gene TNFRSF4 and neoplasm.